Artemis Therapeutics Inc.
ATMS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $311 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $54 | $0 | $0 | $0 |
| Gross Profit | $257 | $0 | $0 | $0 |
| % Margin | 82.6% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $952 | $154 | $167 | $168 |
| SG&A Expenses | $1,616 | $154 | $167 | $168 |
| Sales & Mktg Exp. | $664 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,616 | $154 | $167 | $168 |
| Operating Income | -$1,359 | -$154 | -$167 | -$168 |
| % Margin | -437% | – | – | – |
| Other Income/Exp. Net | $4 | -$13 | -$7 | -$6 |
| Pre-Tax Income | -$1,355 | -$167 | -$174 | -$174 |
| Tax Expense | -$4 | $13 | -$53 | -$53 |
| Net Income | -$1,351 | -$180 | -$121 | -$121 |
| % Margin | -434.4% | – | – | – |
| EPS | -0.01 | -0.007 | -0.024 | -0.024 |
| % Growth | -44.9% | 70.6% | 0% | – |
| EPS Diluted | -0.01 | -0.007 | -0.024 | -0.024 |
| Weighted Avg Shares Out | 57,058,283 | 26,139 | 5,153 | 5,153 |
| Weighted Avg Shares Out Dil | 57,058,283 | 26,139 | 5,153 | 5,153 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $13 | $7 | $6 |
| Depreciation & Amortization | $16 | $237 | $206 | $172 |
| EBITDA | -$1,343 | -$154 | -$167 | -$168 |
| % Margin | -431.8% | – | – | – |